Ketamine Therapy Clinics in the United States: 2026 Statistical Analysis

Original data analysis of the ketamine therapy provider landscape across all 50 states and DC, compiled from the Spravato REMS registry and ASKP member directory.

Data compiled and analyzed by DrugsRegistry.com · Published April 16, 2026 · Licensed under CC BY 4.0

Key Findings

As of July 2026, this directory contains 4,067 source records across 51 states and the District of Columbia in the United States. Of these, 3,768 (92.6%) are current outpatient Spravato locator records, and 299 (7.4%) are current ASKP directory records. One organization can appear in both sources, so these figures should not be interpreted as a count of unique businesses. California leads in total records (384), while Nebraska has the highest per-capita density at 32.5 records per million residents.

Contents

  1. Data Sources and Methodology
  2. National Overview
  3. Providers by State
  4. Clinic Density Per Capita
  5. Top Cities
  6. Provider Specialties
  7. Data Source Breakdown
  8. How to Cite

1. Data Sources and Methodology

This analysis draws on two primary data sources:

  1. Spravato REMS Registry — The FDA-mandated Risk Evaluation and Mitigation Strategy registry of healthcare facilities certified to administer Spravato (esketamine) nasal spray. This registry is maintained by Janssen Pharmaceuticals and the FDA. It contains 3,768 certified treatment centers.
  2. ASKP Member Directory — The American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP) maintains a directory of its member clinics. This directory contains 299 member practices.

Records were cross-referenced using provider name, address, and NPI (National Provider Identifier) number to identify overlapping entries. 0 providers appear in both sources. After deduplication, the combined dataset contains 4,067 unique providers.

Provider credentials and specialties were verified against the CMS NPI Registry (NPPES) when NPI numbers were available. Population estimates are based on U.S. Census Bureau 2024 estimates.

This data represents certified and registered providers only. The actual number of practitioners offering ketamine therapy in the United States may be higher, as some providers administer ketamine without ASKP membership or Spravato certification (e.g., anesthesiologists providing off-label IV ketamine infusions).

2. National Overview

4,067 ketamine therapy providers across 51 states and DC

MetricCountPercentage
Total unique providers4,067100%
Spravato REMS-certified centers3,76892.6%
ASKP member clinics2997.4%
Listed in both registries00.0%
Spravato-only (not ASKP)3,76892.6%
ASKP-only (not Spravato-certified)2997.4%
States with at least one provider51100% of states

The dominance of Spravato REMS-certified centers (92.6% of all providers) reflects the growth of the FDA-approved pathway since esketamine’s approval in March 2019. ASKP member clinics, which more commonly offer IV ketamine infusions and ketamine-assisted psychotherapy (KAP), represent a smaller but clinically significant segment of the market.

3. Providers by State

All 51 states and the District of Columbia have at least one registered ketamine therapy provider. The top 5 states by total provider count are California (384), Texas (373), Florida (270), New York (220), and Illinois (161).

# State Total Providers Spravato ASKP Per 1M Pop.
1 California 384 340 44 9.8
2 Texas 373 341 32 12.2
3 Florida 270 246 24 11.9
4 New York 220 209 11 11.2
5 Illinois 161 157 4 12.9
6 Ohio 151 145 6 12.8
7 New Jersey 133 127 6 14.3
8 Arizona 122 107 15 16.5
9 North Carolina 119 114 5 11.1
10 Virginia 111 104 7 12.8
11 Massachusetts 107 100 7 15.3
12 Tennessee 99 93 6 13.9
13 Maryland 96 94 2 15.5
14 Utah 95 92 3 27.9
15 Washington 92 78 14 11.8
16 Michigan 91 87 4 9.1
17 Pennsylvania 86 79 7 6.7
18 Colorado 85 64 21 14.4
19 Indiana 80 77 3 11.6
20 Georgia 74 66 8 6.7
21 Kansas 71 69 2 24.5
22 Missouri 71 70 1 11.5
23 Kentucky 70 69 1 15.6
24 Iowa 68 63 5 21.3
25 Nebraska 65 63 2 32.5
26 Connecticut 64 60 4 17.8
27 Oklahoma 62 60 2 15.1
28 Louisiana 60 58 2 13.0
29 Arkansas 60 59 1 19.4
30 Oregon 54 49 5 12.9
31 Minnesota 52 49 3 9.1
32 South Carolina 44 41 3 8.1
33 Alabama 41 38 3 8.0
34 Idaho 40 34 6 20.0
35 Nevada 39 36 3 12.2
36 Wisconsin 37 32 5 6.3
37 Mississippi 33 32 1 11.4
38 West Virginia 27 27 0 15.0
39 Montana 22 18 4 20.0
40 New Hampshire 21 20 1 15.0
41 Rhode Island 18 17 1 16.4
42 New Mexico 16 13 3 7.6
43 South Dakota 15 13 2 16.5
44 Maine 13 13 0 9.3
45 Alaska 13 13 0 17.8
46 Delaware 12 10 2 12.0
47 Wyoming 8 4 4 13.8
48 Vermont 7 5 2 10.8
49 District of Columbia 5 4 1 7.2
50 North Dakota 5 4 1 6.4
51 Hawaii 5 5 0 3.6

4. Clinic Density Per Capita

Adjusting for population reveals a different geographic picture. States with the highest per-capita provider density are not necessarily the most populous. Nebraska leads with 32.5 providers per million residents, followed by Utah (27.9) and Kansas (24.5).

National average density: 12.1 providers per million residents (based on estimated 2024 US population of 335 million)

# State Per 1M Residents Total Providers Population (est.)
1 Nebraska 32.5 65 2.0M
2 Utah 27.9 95 3.4M
3 Kansas 24.5 71 2.9M
4 Iowa 21.3 68 3.2M
5 Idaho 20.0 40 2.0M
6 Montana 20.0 22 1.1M
7 Arkansas 19.4 60 3.1M
8 Alaska 17.8 13 0.7M
9 Connecticut 17.8 64 3.6M
10 Arizona 16.5 122 7.4M
11 South Dakota 16.5 15 0.9M
12 Rhode Island 16.4 18 1.1M
13 Kentucky 15.6 70 4.5M
14 Maryland 15.5 96 6.2M
15 Massachusetts 15.3 107 7.0M

The lowest-density states are Hawaii (3.6 per 1M), suggesting that geographic isolation and market size limit provider availability. Patients in low-density states may need to travel to access ketamine therapy or consider telehealth-based oral ketamine programs.

5. Top Cities by Provider Count

Major metropolitan areas concentrate the most providers. New York City leads with 45 providers, followed by Houston (44) and San Antonio (33).

# City Total Providers Spravato ASKP
1 Houston, TX 45 41 4
2 New York, NY 44 42 2
3 San Antonio, TX 33 31 2
4 Austin, TX 31 24 7
5 Omaha, NE 30 29 1
6 Phoenix, AZ 24 21 3
7 Chicago, IL 24 23 1
8 Dallas, TX 24 23 1
9 San Diego, CA 21 19 2
10 Las Vegas, NV 20 19 1
11 Miami, FL 20 18 2
12 Portland, OR 19 16 3
13 Tampa, FL 19 18 1
14 Sacramento, CA 17 15 2
15 Tucson, AZ 17 16 1
16 Lincoln, NE 16 15 1
17 Gilbert, AZ 16 11 5
18 Los Angeles, CA 16 15 1
19 Denver, CO 16 13 3
20 Brooklyn, NY 16 16 0

6. Provider Specialties

Of the 511 providers with NPI data available, the most common specialties are psychiatry, nurse practitioner (psychiatric), and anesthesiology. This reflects the multidisciplinary nature of ketamine therapy, which spans psychiatric, anesthesia, and primary care settings.

Specialty Count % of NPI-Verified
Psychiatry & Neurology, Psychiatry 141 27.6%
Nurse Practitioner, Psych/Mental Health 56 11.0%
Clinic/Center, Mental Health (Including Community Mental Health Center) 34 6.7%
Emergency Medicine 21 4.1%
Nurse Anesthetist, Certified Registered 18 3.5%
Anesthesiology 14 2.7%
Family Medicine 14 2.7%
Clinic/Center, Multi-Specialty 13 2.5%
Community/Behavioral Health 13 2.5%
Clinic/Center 10 2.0%

The presence of emergency medicine physicians (21) and family medicine practitioners (14) among ketamine providers indicates that ketamine therapy is not limited to psychiatric or anesthesia practices, though these remain the dominant specialties.

7. Data Source Overlap Analysis

The two primary data sources (Spravato REMS registry and ASKP directory) have limited overlap, indicating they capture distinct segments of the ketamine therapy market:

  • 3,768 providers (92.6%) appear only in the Spravato REMS registry — these are facilities certified to administer esketamine nasal spray but not ASKP members
  • 299 providers (7.4%) appear only in the ASKP directory — these typically focus on IV ketamine, IM ketamine, or KAP without Spravato certification
  • 0 providers (0.0%) appear in both sources — full-service ketamine clinics offering both Spravato and other ketamine modalities

The low overlap rate (0.0%) underscores that Spravato REMS centers and ASKP member clinics serve different market segments. Aggregating both sources is essential for a comprehensive picture of ketamine therapy availability in the United States.

8. How to Cite This Data

This data is published under a Creative Commons Attribution 4.0 (CC BY 4.0) license. You are free to share and adapt this data for any purpose, including commercial use, provided you give appropriate credit.

Suggested citation: DrugsRegistry.com. “Ketamine Therapy Clinics in the United States: 2026 Statistical Analysis.” Published April 16, 2026. https://drugsregistry.com/ketamine-clinics-statistics/. Accessed [date].

For researchers: This analysis is a dated snapshot compiled from the Spravato REMS and ASKP directories. ASKP is a voluntary membership directory, not a government registry, and every current status should be checked against the original source.

Data Sources

  1. Janssen Pharmaceuticals. Spravato treatment-center locator. official locator. Accessed July 2026; directory includes outpatient locations reporting treatment within the last six months.
  2. American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP). Member Provider Directory. official directory. Accessed July 2026.
  3. Centers for Medicare & Medicaid Services. National Plan and Provider Enumeration System (NPPES) NPI Registry. https://npiregistry.cms.hhs.gov/. Used for provider credential and specialty verification.
  4. U.S. Census Bureau. State Population Estimates, 2024. Used for per-capita density calculations.